Expression and function of CD9 in melanoma cells

Molecular Carcinogenesis

Volumn 49, Issue 1, 2010, Pages 85-93

  Fan, Jun ^a   Zhu, Guo Zhang ^a   Niles, Richard M ^a  

^a MARSHALL UNIVERSITY   (United States)

Author keywords

Anchorage independent growth; CD9; Human melanoma; Matrigel invasion; Tetraspanins

Indexed keywords

CD9 ANTIGEN; COMPLEMENTARY DNA; HISTONE DEACETYLASE INHIBITOR; MATRIGEL; TRICHOSTATIN A;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA METHYLATION; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD; AZACITIDINE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INFANT, NEWBORN; MELANOCYTES; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSFECTION;

EID: 74249094505     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20580     Document Type: Article

References (28)

1. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009;27:3-9.
2. Carlson JA, Slominski A, Linette GP, et al. Malignant melanoma 2003: Predisposition, diagnosis, prognosis, and staging. Am J Clin Pathol 2003;120:S101-S127.
3. Chin L. The genetics of malignant melanoma: Lessons from mouse and man. Nat Rev Cancer 2003;3:559-570.
4. Hocker TL, Singh MK, Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: Moving from the benchside to the bedside. J Invest Dermatol 2008;128: 2575-2595.
5. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005;10:801-811.
6. Boucheix C, Duc GH, Jasmin C, Rubinstein E. Tetraspanins and malignancy. Expert Rev Mol Med 2001;31:1-17.
7. Levy S, Shoham T. The tetraspanin web modulates immune signaling complexes. Nat Rev Immunol 2005;5:136-148.
8. Boucheix C, Rubinstein E. Tetraspanins. Cell Mol Life Sci 2001;58:1189-1205.
9. Rubinstein E, Le Nour F, Lagaudriere-Gasbert C, Billard M, Conjeaud H, Boucheix C. CD9, CD63, CD61, CD81, and CD82 are components of a surface tetraspanin network connected to HLA-DR and VLA integrins. Eur J Immunol 1996;26:2657-2665.
10. Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M. Suppression of cell motility and metastasis by transfection with motility-related protein (MRP-1/CD9) DNA. J Exp Med 1993;177:1231-1237.
11. Miyake M, Nakano K, Icki Y, et al. Motility related protein 1 (MRP-1/CD9) expression: Inverse correlation with metastases in breast cancer. Cancer Res 1995;55:4127-4131.
12. Cajot JF, Sordat I, Silverstre T, Sordat B. Differential display cloning identifies motility-related protein (MRP1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells. Cancer Res 1997;57:2593-2597.
13. Wang J-C, Begin LR, Berube NG, et al. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications. Clin Cancer Res 2007;13:2354-2361.
14. Longo N, Yanez-Mo M, Mittelbrunn M, et al. Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood 2001;98:3717-3726.
15. Le Nour F, Andre M, Greco C, et al. Profiling of the tetraspanin web of human colon cancer cells. Mol Cell Proteomics 2006;5:845-857.
16. Si Z, Hersey P. Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanoma. Int J Cancer 1993;54:37-43.
17. Garcia-Lopez MA, Barriero O, Garcia-Diez A, Sanchez-Madrid F, Penas PF. Role of tetraspanins CD9 and CD151 in primary melanocyte motility. J Invest Dermatol 2005;124: 1001-1009.
18. Mischiati C, Natali PG, Sereni A, Sibilio L, Grammatico P, Giacomini P. cDNA - Array profiling of melanoma and paired melanocytes cultures. J Cell Physiol 2006;207:697-705.
19. Rambow F, Malek O, Geffrotin C, et al. Identification of differentially expressed genes in spontaneously regressing melanoma using the MeLIM swine model. Pigment Cell Melanoma Res 2008;21:147-161.
20. Bennett DC, Cooper PJ, Hart IR. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumor promoter for growth. Int J Cancer 1987; 38:414-418.
21. Zhu GZ, Miller BJ, Boucheix C, et al. Residues SFQ (173-175) in the large extracellular loop of CD9 are required for gamete fusion. Development 2002;129:1995-2002.
22. Iguchi T, Sakata K, Yoshizaki K, Tago K, Mizuno N, Itoh H. Orphan G protein-coupled receptor GPR56 regulates neural progenitor cell migration via a G-alpha 12/13 and Rho pathway. J Biol Chem 2008;283:14469-14478.
23. Huang Y, Fan J, Zhu GZ. Characterization of GPR56 protein and its suppressed expression in human pancreatic cancer cells. Mol Cell Biochem 2008;308:133-139.
24. Hori H, Yano S, Koufuji K, Takeda J, Shirouzu K. CD9 expression in gastric cancer and its significance. J Surg Res 2004;117:208-215.
25. Mitsuzuka K, Handa K, Satoh M, Arai Y, Hakomori S. A specific microdomain (glycosynapse 3″) controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha-3-beta-1 integrin with CD9. J Biol Chem 2005;280:35545-35553.
26. Drucker L, Tohami T, Tartakover-Matalon S, et al. Promoter hypermethylation of tetraspanin members contributes to the silencing in myeloma cell lines. Carcinogenesis 2006;26: 197-204.
27. Zhang S, Fields CR, Su N, Pan YX, Robertson KD. Pharmacologic inhibition of epigenetic modifications coupled with gene expression profiling reveals normal targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 2007;261:2621-2634.
28. Wang XQ, Alfaro ML, Evans GF, Zuckerman SH. Histone deacetylase inhibition results in decreased macrophage CD9 expression. Biochem Biophys Res Commun 2002;294:660-666.